Curing All Patients with Acute Promyelocytic Leukemia: Are We There Yet?

Hematology/Oncology Clinics of North America

Volumn 25, Issue 6, 2011, Pages 1215-1233

  Baljevic, Muhamed ^a   Park, Jae H ^b   Stein, Eytan ^b   Douer, Dan ^b   Altman, Jessica K ^c   Tallman, Martin S ^b  

^a WEILL CORNELL MEDICAL CENTER   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Acute promyelocytic leukemia; All trans retinoic acid; Arsenic trioxide; Cure; Targeted therapies

Indexed keywords

ANTHRACYCLINE; CYTARABINE; DAUNORUBICIN; FIBRINOGEN; FLT3 LIGAND; FRESH FROZEN PLASMA; MITOXANTRONE; RETINOIC ACID RECEPTOR ALPHA; TAMIBAROTENE;

ACUTE GRANULOCYTIC LEUKEMIA; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER REGRESSION; CANCER SURVIVAL; CHROMOSOME 15; CHROMOSOME 17; CONVALESCENCE; CRYOPRECIPITATE; DRUG DOSE REDUCTION; DRUG EFFICACY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; LEUKOCYTE COUNT; MINIMAL RESIDUAL DISEASE; MOLECULARLY TARGETED THERAPY; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROMYELOCYTE; PROMYELOCYTIC LEUKEMIA; RELAPSE; REVIEW; SENSITIVITY AND SPECIFICITY; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA;

CONSOLIDATION CHEMOTHERAPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INDUCTION CHEMOTHERAPY; LEUKEMIA, PROMYELOCYTIC, ACUTE; MAINTENANCE CHEMOTHERAPY; NEOPLASM, RESIDUAL;

EID: 81255177098     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2011.10.002     Document Type: Review

References (87)

1. Tallman M.S., Altman J.K. Curative strategies in acute promyelocytic leukemia. Hematology Am Soc Hematol Educ Program 2008, 391-399.
2. Bennett J.M., Catovsky D., Daniel M.T., et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 1976, 33(4):451-458.
3. Rowley J.D., Golomb H.M., Dougherty C. 15/17 translocation, a consistent chromosomal change in acute promyelocytic leukaemia. Lancet 1977, 1(8010):549-550.
4. Grignani F., Ferrucci P.F., Testa U., et al. The acute promyelocytic leukemia-specific PML-RAR alpha fusion protein inhibits differentiation and promotes survival of myeloid precursor cells. Cell 1993, 74(3):423-431.
5. Hillestad L.K. Acute promyelocytic leukemia. Acta Med Scand 1957, 159:189-194.
6. Guidez F., Ivins S., Zhu J., et al. Reduced retinoic acid-sensitivities of nuclear receptor corepressor binding to PML- and PLZF-RARalpha underlie molecular pathogenesis and treatment of acute promyelocytic leukemia. Blood 1998, 91:2634.
7. Melnick A., Licht J.D. Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 1999, 93:3167.
8. Dong S., Tweardy D.J. Interactions of STAT5b-RARalpha, a novel acute promyelocytic leukemia fusion protein, with retinoic acid receptor and STAT3 signaling pathways. Blood 2002, 99:2637.
9. Gale R.E., Hills R., Pizzey A.R., et al. Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia. Blood 2005, 106:3768-3776.
10. Barragán E., Montesinos P., Camos M., et al. Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy. Haematologica 2011, 96(10):1470-1477.
11. Tallman M.S., Kwaan H.C. Reassessing the hemostatic disorder associated with acute promyelocytic leukemia. Blood 1992, 79(3):543-553.
12. Cunningham I., Gee T.S., Reich L.M., et al. Acute promyelocytic leukemia: treatment results during a decade at Memorial Hospital. Blood 1989, 73(5):1116-1122.
13. Fenaux P., Degos L. Treatment of acute promyelocytic leukemia with all-trans retinoic acid. Leuk Res 1991, 15(8):655-657.
14. Head D.R., Kopecky K.J., Willman C., et al. Treatment outcome with chemotherapy in acute promyelocytic leukemia: the Southwest Oncology Group (SWOG) experience. Leukemia 1994, 8(Suppl 2):S38-S41.
15. Degos L., Dombret H., Chomienne C., et al. All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia. Blood 1995, 85(10):2643-2653.
16. Huang M.E., Ye Y.C., Chen S.R., et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988, 72(2):567-572.
17. Tallman M.S., Andersen J.W., Schiffer C.A., et al. All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med 1997, 337(15):1021-1028.
18. Chen Z.X., Xue Y.Q., Zhang R., et al. A clinical and experimental study on all-trans retinoic acid-treated acute promyelocytic leukemia patients. Blood 1991, 78(6):1413-1419.
19. Castaigne S., Chomienne C., Daniel M.T., et al. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood 1990, 76(9):1704-1709.
20. Fenaux P., Chastang C., Chevret S., et al. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood 1999, 94(4):1192-1200.
21. Lengfelder E., Reichert A., Schoch C., et al. Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia. German AML Cooperative Group. Leukemia 2000, 14(8):1362-1370.
22. Mandelli F., Diverio D., Avvisati G., et al. Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. Blood 1997, 90(3):1014-1021.
23. Asou N., Adachi K., Tamura J., et al. Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Japan Adult Leukemia Study Group. J Clin Oncol 1998, 16(1):78-85.
24. Sanz M.A., Martin G., Rayon C., et al. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia. PETHEMA group. Blood 1999, 94(9):3015-3021.
25. Berman E., Little C., Kher U., et al. Prognostic analysis of patients with acute promyelocytic leukemia. Blood 1991, 78:43a. [abstract].
26. Avvisati G., Lo Coco F., Diverio D., et al. AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) pilot study. Blood 1996, 88(4):1390-1398.
27. Burnett AK, Hills RK, Grimwade D, et al. Idarubicin and ATRA is as effective as MRC chemotherapy in patients with acute promyelocytic leukaemia with lower toxicity and resource usage: preliminary results of the MRC AML15 Trial. ASH Annual Meeting Abstracts. 2007;110(11):589.
28. Ades L., Chevret S., Raffoux E., et al. Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group. J Clin Oncol 2006, 24(36):5703-5710.
29. Ades L, Raffoux E, Chevret S, et al. Is AraC required in the treatment of standard risk APL? Long term results of a randomized trial (APL 2000) from the French Belgian Swiss APL Group. ASH Annual Meeting Abstracts. 2010;116(21):13.
30. O'Donnell M.R., Abboud C.N., Altman J., et al. Acute myeloid leukemia. J Natl Compr Canc Netw 2011, 9(3):280-317.
31. Sanz M.A., Montesinos P., Rayon C., et al. Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. Blood 2010, 115(25):5137-5146.
32. Lo-Coco F., Avvisati G., Vignetti M., et al. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group. Blood 2010, 116(17):3171-3179.
33. Sanz M.A., Martin G., Gonzalez M., et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood 2004, 103(4):1237-1243.
34. Sanz M.A., Vellenga E., Rayon C., et al. All-trans retinoic acid and anthracycline monochemotherapy for the treatment of elderly patients with acute promyelocytic leukemia. Blood 2004, 104(12):3490-3493.
35. Sanz M.A., Lo Coco F., Martin G., et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood 2000, 96(4):1247-1253.
36. Powell B.L., Moser B., Stock W., et al. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood 2010, 116(19):3751-3757.
37. Flanagan S.A., Meckling K.A. All- trans-retinoic acid increases cytotoxicity of 1-beta-D-arabinofuranosylcytosine in NB4 cells. Cancer Chemother Pharmacol 2003, 51(5):363-375.
38. Tallman M.S., Andersen J.W., Schiffer C.A., et al. All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood 2002, 100(13):4298-4302.
39. Ades L., Guerci A., Raffoux E., et al. Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience. Blood 2010, 115(9):1690-1696.
40. Avvisati G., Lo-Coco F., Paoloni F.P., et al. AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance. Blood 2011, 117(18):4716-4725.
41. Asou N., Kishimoto Y., Kiyoi H., et al. A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML-RARalpha transcript after consolidation therapy: the Japan Adult Leukemia Study Group (JALSG) APL97 study. Blood 2007, 110(1):59-66.
42. Avvisati G., Petti M.C., Lo Coco F., et al. AIDA: the Italian way of treating acute promyelocytic leukemia (APL), final act. Blood 2003, 102(Suppl 1). [abstract 487].
43. Lo Coco F., Diverio D., Falini B., et al. Genetic diagnosis and molecular monitoring in the management of acute promyelocytic leukemia. Blood 1999, 94(1):12-22.
44. Grimwade D., Lo Coco F. Acute promyelocytic leukemia: a model for the role of molecular diagnosis and residual disease monitoring in directing treatment approach in acute myeloid leukemia. Leukemia 2002, 16(10):1959-1973.
45. Lo Coco F., Diverio D., Avvisati G., et al. Therapy of molecular relapse in acute promyelocytic leukemia. Blood 1999, 94(7):2225-2229.
46. Esteve J., Escoda L., Martin G., et al. Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all-trans retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99): benefit of an early intervention. Leukemia 2007, 21(3):446-452.
47. Thirugnanam R., George B., Chendamarai E., et al. Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen. Biol Blood Marrow Transplant 2009, 15(11):1479-1484.
48. Grimwade D., Jovanovic J.V., Hills R.K., et al. Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. J Clin Oncol 2009, 27(22):3650-3658.
49. Park J.H., Tallman M.S. Managing acute promyelocytic leukemia without conventional chemotherapy: is it possible?. Expert Rev Hematol 2011, 4(4):427-436.
50. Grimwade D., Tallman M.S. Should minimal residual disease monitoring be the standard of care for all patients with acute promyelocytic leukemia?. Leuk Res 2011, 35(1):3-7.
51. Meloni G., Diverio D., Vignetti M., et al. Autologous bone marrow transplantation for acute promyelocytic leukemia in second remission: prognostic relevance of pretransplant minimal residual disease assessment by reverse-transcription polymerase chain reaction of the PML/RAR alpha fusion gene. Blood 1997, 90(3):1321-1325.
52. Lallemand-Breitenbach V., Guillemin M.C., Janin A., et al. Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia. J Exp Med 1999, 189(7):1043-1052.
53. de Botton S., Sanz M.A., Chevret S., et al. Extramedullary relapse in acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Leukemia 2006, 20:35-41.
54. de Botton S., Fawaz A., Chevret S., et al. Autologous and allogeneic stem-cell transplantation as salvage treatment of acute promyelocytic leukemia initially treated with all-trans-retinoic acid: a retrospective analysis of the European acute promyelocytic leukemia group. J Clin Oncol 2005, 23:120-126.
55. de la Serna J., Montesinos P., Vellenga E., et al. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood 2008, 111(7):3395-3402.
56. Breccia M., Latagliata R., Cannella L., et al. Early hemorrhagic death before starting therapy in acute promyelocytic leukemia: association with high WBC count, late diagnosis and delayed treatment initiation. Haematologica 2010, 95(5):853-854.
57. Alizadeh A.A., McClellan J.S., Gotlib J.R., et al. Early mortality in acute promyelocytic leukemia may be higher than previously reported. Blood 2009, 114:1015.
58. Micol J, Raffoux E, Boissel N, et al. Do early events excluding patients with acute promyelocytic leukemia (APL) from trial enrollment modify treatment result evaluation? Real-life management of 100 patients referred to the University Hospital Saint-Louis between 2000 and 2010. Blood (ASH Annual Meeting Abstracts), 116, Abstract 1083 (2010).
59. Park J.H., Qiao B., Panageas K.S., et al. Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. Blood 2011, 118(5):1248-1254.
60. Di Bona E., Avvisati G., Castaman G., et al. Early haemorrhagic morbidity and mortality during remission induction with or without all-trans retinoic acid in acute promyelocytic leukaemia. Br J Haematol 2000, 108(4):689-695.
61. Visani G., Gugliotta L., Tosi P., et al. All-trans retinoic acid significantly reduces the incidence of early hemorrhagic death during induction therapy of acute promyelocytic leukemia. Eur J Haematol 2000, 64(3):139-144.
62. Sanz M.A., Grimwade D., Tallman M.S., et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2009, 113(9):1875-1891.
63. Dimov N.D., Medeiros L.J., Kantarjian H.M., et al. Rapid and reliable confirmation of acute promyelocytic leukemia by immunofluorescence staining with an antipromyelocytic leukemia antibody. Cancer 2010, 116(2):369-376.
64. Rego EM, Kim H, Ruiz-Arguelles GJ, et al. Improving the treatment outcome of acute promyelocytic leukemia in developing countries through international cooperative network. Report on the International Consortium on Acute Promyelocytic Leukemia Study Group. ASH Annual Meeting Abstracts. 2009;114(6).
65. Andersen M.K., Pedersen-Bjergaard J. Therapy-related MDS and AML in acute promyelocytic leukemia. Blood 2002, 100(5):1928-1929. [author reply: 1929].
66. Garcia-Manero G., Kantarjian H.M., Kornblau S., et al. Therapy-related myelodysplastic syndrome or acute myelogenous leukemia in patients with acute promyelocytic leukemia (APL). Leukemia 2002, 16(9):1888.
67. Latagliata R., Petti M.C., Fenu S., et al. Therapy-related myelodysplastic syndrome-acute myelogenous leukemia in patients treated for acute promyelocytic leukemia: an emerging problem. Blood 2002, 99(3):822-824.
68. Hu J., Shen Z.X., Sun G.L., et al. Long-term survival and prognostic study in acute promyelocytic leukemia treated with all-trans-retinoic acid, chemotherapy, and As2O3: an experience of 120 patients at a single institution. Int J Hematol 1999, 70(4):248-260.
69. Shen Z.X., Chen G.Q., Ni J.H., et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997, 89:3354-3360.
70. Soignet S.L., Maslak P., Wang Z.G., et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998, 339:1341-1348.
71. Nasr R., Guillemin M.C., Ferhi O., et al. Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation. Nat Med 2008, 14(12):1333-1342.
72. Licht J.D. Acute promyelocytic leukemia-weapons of mass differentiation. N Engl J Med 2009, 360(9):928-930.
73. Ablain J., de The H. Revisiting the differentiation paradigm in acute promyelocytic leukemia. Blood 2011, 117(22):5795-5802.
74. Zhu J., Gianni M., Kopf E., et al. Retinoic acid induces proteasome-dependent degradation of retinoic acid receptor alpha (RARalpha) and oncogenic RARalpha fusion proteins. Proc Natl Acad Sci U S A 1999, 96(26):14807-14812.
75. Shao W., Fanelli M., Ferrara F.F., et al. Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells. J Natl Cancer Inst 1998, 90(2):124-133.
76. Chen G.Q., Shi X.G., Tang W., et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood 1997, 89(9):3345-3353.
77. Zheng P.Z., Wang K.K., Zhang Q.Y., et al. Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia. Proc Natl Acad Sci U S A 2005, 102(21):7653-7658.
78. Gianni M., Koken M.H., Chelbi-Alix M.K., et al. Combined arsenic and retinoic acid treatment enhances differentiation and apoptosis in arsenic-resistant NB4 cells. Blood 1998, 91(11):4300-4310.
79. Mathews V., George B., Chendamarai E., et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data. J Clin Oncol 2010, 28(24):3866-3871.
80. Ghavamzadeh A., Alimoghaddam K., Rostami S., et al. Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia. J Clin Oncol 2011, 29(20):2753-2757.
81. Shen Z.X., Shi Z.Z., Fang J., et al. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A 2004, 101(15):5328-5335.
82. Hu J., Liu Y.F., Wu C.F., et al. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A 2009, 106(9):3342-3347.
83. Estey E., Garcia-Manero G., Ferrajoli A., et al. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood 2006, 107(9):3469-3473.
84. Ravandi F, Estey EH, Cortes JE, et al. Phase II study of all-trans retinoic acid (ATRA), arsenic trioxide (ATO), with or without gemtuzumab ozogamicin (GO) for the frontline therapy of patients with acute promyelocytic leukemia (APL). Blood (ASH Annual Meeting Abstracts). 116, Abstract 1080 (2010).
85. Iland H, Frank F, Supple S. et al. Interim analysis of the APML4 trial incorporating all-trans retinoic acid (ATRA), idarubicin, and intravenous arsenic trioxide (ATO) as initial therapy in acute promyelocytic leukaemia (APL): an Australasian Leukaemia and Lymphoma Group (ALLG) study. International Oral Arsenic Union & 38th Annual Scientific Meeting Hong Kong Society of Haematology 2010;16 [abstract 6].
86. Gore S.D., Gojo I., Sekeres M.A., et al. Single cycle of arsenic trioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemia. J Clin Oncol 2010, 28(6):1047-1053.
87. Di Veroli A., Ramadan S.M., Divona M., et al. Molecular remission in advanced acute promyelocytic leukaemia after treatment with the oral synthetic retinoid Tamibarotene. Br J Haematol 2010, 151(1):99-101.